| 000 | 05389nam a2200817 i 4500 | ||
|---|---|---|---|
| 001 | 20210093800 | ||
| 003 | CtWfDGI | ||
| 005 | 20220524144101.0 | ||
| 006 | m o d | ||
| 007 | cr zn||||uuuuu | ||
| 008 | 210331t20212020enkad ob 001 0 eng d | ||
| 020 |
_a9781789249958 _q(epdf) |
||
| 020 |
_a9781789249965 _q(epub) |
||
| 020 |
_z9781789249941 _q(Hbk) |
||
| 040 |
_aCtWfDGI _beng _erda _cCtWfDGI |
||
| 050 | 1 | 4 |
_aSF977.M94 _bM936 2021eb |
| 082 | 0 | 4 |
_a636.4/0896 _223 |
| 245 | 0 | 0 |
_aMycoplasmas in swine / _cedited by Dominiek Maes, Marina Sibila & Maria Pieters. |
| 264 | 1 |
_aWallingford, Oxfordshire, UK : _bCABI, _c[2021] |
|
| 264 | 4 | _c�2020 | |
| 300 |
_a1 online resource (344 pages) : _billustrations, charts |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 504 | _aIncludes bibliographical references and index. | ||
| 520 | 3 | _aThis book contains 14 chapters that discuss the genetics, epidemiology, prevalence, pathogenesis, clinical signs, diagnosis, treatment, prevention and control of Mycoplasma infections in pigs. Chapter 1 discusses the phylogenetics and classification of Mycoplasma species in pigs; Chapter 2 describes the genomic diversity and antigenic variation of Mycoplasma hyopneumoniae strains; Chapter 3 discusses the pathogenesis, virulence factor and pathogenicity of Mycoplasma hyopneumoniae; Chapter 4 discusses the molecular epidemiology, risk factors, transmission and prevalence of Mycoplasma hyopneumoniae, Chapter 5 discusses the clinical signs and gross lesions of Mycoplasma hyopneumoniae infection; Chapter 6 discusses immune responses against Mycoplasma infections; Chapter 7 describes the interactions of Mycoplasma hyopneumoniae with other pathogens and their economic impact; Chapter 8 discusses the diagnosis of Mycoplasma hyopneumoniae infection and its associated diseases; Chapter 9 describes the general control measures against Mycoplasma hyopneumoniae infections; Chapter 10 describes the selection and efficacy of antimicrobials against Mycoplasma hyopneumoniae infections; Chapter 11 discusses the development and efficacy of vaccines against Mycoplasma hyopneumoniae; Chapter 12 describes the eradication of Mycoplasma hyopneumoniae in pig herds; Chapter 13 describes the epidemiology, prevalence, pathogenesis, clinical signs, diagnosis, treatment, prevention and control of Mycoplasma hyorhinis and Mycoplasma hyosynoviae in pig herds and Chapter 14 discusses the epidemiology, prevalence, transmission, pathogenesis, clinical signs, diagnosis, treatment, prevention, control and economic impact of Mycoplasma suis infection in pigs. | |
| 505 | 0 | _aOverview of the general characteristics and classification of porcine Mycoplasma species -- Diversity of Mycoplasma hyopneumoniae strains -- Mycoplasma hyopneumoniae pathogenicity: the known and the unknown -- Epidemiology of Mycoplasma hyopneumoniae infections -- Mycoplasma hyopneumoniae clinical signs and gross lung lesions, including monitoring -- Immune responses against porcine Mycoplasma infections -- Interactions of Mycoplasma hyopneumoniae with other pathogens and economic impact -- Diagnosis of Mycoplasma hyopneumoniae infection and associated diseases -- General control measures against Mycoplasma hyopneumoniae infections -- Antimicrobial treatment of Mycoplasma hyopneumoniae infections -- Vaccines and vaccination against Mycoplasma hyopneumoniae -- Eradication of Mycoplasma hyopneumoniae from pig herds -- Mycoplasma hyorhinis and Mycoplasma hyosynoviae in pig herds -- Mycoplasma suis infections in pigs. | |
| 588 | _aTitle from PDF title page (viewed March 31, 2021). | ||
| 506 | _aAccess limited to subscribing institution. | ||
| 530 | _aAlso available in print format. | ||
| 650 | 0 |
_aSwine _xDiseases. |
|
| 650 | 0 | _aMycoplasma diseases in animals. | |
| 650 | 7 |
_aAnimal pathology. _2cabt |
|
| 650 | 7 |
_aAntibiotics. _2cabt |
|
| 650 | 7 |
_aAntigenic variation. _2cabt |
|
| 650 | 7 |
_aClinical aspects. _2cabt |
|
| 650 | 7 |
_aDiagnosis. _2cabt |
|
| 650 | 7 |
_aDiagnostic techniques. _2cabt |
|
| 650 | 7 |
_aDisease control. _2cabt |
|
| 650 | 7 |
_aDisease distribution. _2cabt |
|
| 650 | 7 |
_aDisease prevalence. _2cabt |
|
| 650 | 7 |
_aDisease prevention. _2cabt |
|
| 650 | 7 |
_aDisease transmission. _2cabt |
|
| 650 | 7 |
_aDrug resistance. _2cabt |
|
| 650 | 7 |
_aDrug therapy. _2cabt |
|
| 650 | 7 |
_aEconomic impact. _2cabt |
|
| 650 | 7 |
_aEfficacy. _2cabt |
|
| 650 | 7 |
_aEpidemiology. _2cabt |
|
| 650 | 7 |
_aGenes. _2cabt |
|
| 650 | 7 |
_aGenetic diversity. _2cabt |
|
| 650 | 7 |
_aGenetics. _2cabt |
|
| 650 | 7 |
_aImmune response. _2cabt |
|
| 650 | 7 |
_aImmunity. _2cabt |
|
| 650 | 7 |
_aLesions. _2cabt |
|
| 650 | 7 |
_aMolecular epidemiology. _2cabt |
|
| 650 | 7 |
_aMycoplasmosis. _2cabt |
|
| 650 | 7 |
_aNucleotide sequences. _2cabt |
|
| 650 | 7 |
_aPathogenesis. _2cabt |
|
| 650 | 7 |
_aPhylogenetics. _2cabt |
|
| 650 | 7 |
_aPotency. _2cabt |
|
| 650 | 7 |
_aRisk factors. _2cabt |
|
| 650 | 7 |
_aVaccination. _2cabt |
|
| 650 | 7 |
_aVaccine development. _2cabt |
|
| 650 | 7 |
_aVaccines. _2cabt |
|
| 650 | 7 |
_aBacterial diseases. _2cabt |
|
| 700 | 1 |
_aMaes, Dominiek, _eeditor. |
|
| 700 | 1 |
_aSibila, Marina, _eeditor. |
|
| 700 | 1 |
_aPieters, Maria, _eeditor. |
|
| 710 | 2 |
_aC.A.B. International, _eissuing body. |
|
| 856 | 4 | 0 |
_uhttps://dx.doi.org/10.1079/9781789249941.0000 _zClick here to access resource |
| 999 |
_c212 _d212 |
||